Usefulness of plasma YKL-40 in management of community-acquired pneumonia severity in patients

International Journal of Molecular Sciences

Volumn 14, Issue 11, 2013, Pages 22817-22825

  Wang, Hsiang Ling ^a,b   Hsiao, Pei Ching ^a,c   Tsai, Hsiu Ting ^a   Yeh, Chao Bin ^a,c   Yang, Shun Fa ^a,c  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAICHUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Community acquired pneumonia; Severity; YKL 40

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN; PROTEIN YKL 40; UNCLASSIFIED DRUG;

ADULT; AGE; APACHE; ARTICLE; BLOOD PRESSURE; BREATHING RATE; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; HUMAN; HUMAN CELL; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PNEUMONIA SEVERITY INDEX; PROTEIN BLOOD LEVEL; UREMIA; YKL 40 GENE;

ADIPOKINES; APACHE; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; LECTINS; MALE; MIDDLE AGED; PNEUMONIA;

EID: 84887933527     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141122817     Document Type: Article

References (22)

1. Chiang, T.Y.; Shyu, L.Y.; Tsao, T.C.; Chien, M.H.; Tsao, S.M.; Lee, Y.T.; Yang, S.F. Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia. Clin. Chem. Lab. Med. 2011, 50, 449-454.
2. Lee, Y.T.; Chen, S.C.; Shyu, L.Y.; Lee, M.C.; Wu, T.C.; Tsao, S.M.; Yang, S.F. Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia. Clin. Chim. Acta 2012, 413, 630-635.
3. Houck, P.M.; Bratzler, D.W.; Nsa, W.; Ma, A.; Bartlett, J.G. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. 2004, 164, 637-644.
4. Lee, S.H.; Lin, C.Y.; Wang, P.H.; Han, C.P.; Yang, S.F.; Chang, J.T.; Lee, M.C.; Lin, L.Y.; Lee, M.S. Significant association of elevated concentration of plasma YKL-40 with disease severity in patients with pelvic inflammatory disease. J. Clin. Lab. Anal. 2012, 26, 136-142.
5. Zheng, J.L.; Lu, L.; Hu, J.; Zhang, R.Y.; Zhang, Q.; Chen, Q.J.; Shen, W.F. Genetic polymorphisms in chitinase 3-like 1 (CHI3L1) are associated with circulating YKL-40 levels, but not with angiographic coronary artery disease in a Chinese population. Cytokine 2011, 54, 51-55.
6. Nordenbaek, C.; Johansen, J.S.; Junker, P.; Borregaard, N.; Sørensen, O.; Price, P.A. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J. Infect. Dis. 1999, 180, 1722-1726.
7. Badariotti, F.; Kypriotou, M.; Lelong, C.; Dubos, M.P.; Renard, E.; Galera, P.; Favrel, P. The phylogenetically conserved molluscan chitinase-like protein 1 (Cg-Clp1), homologue of human HC-gp39, stimulates proliferation and regulates synthesis of extracellular matrix components of mammalian chondrocytes. J. Biol. Chem. 2006, 281, 29583-29596.
8. Volck, B.; Price, P.A.; Johansen, J.S.; Sørensen, O.; Benfield, T.L.; Nielsen, H.J.; Calafat, J.; Borregaard, N. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc. Assoc. Am. Physicians 1998, 110, 351-360.
9. Malinda, K.M.; Ponce, L.; Kleinman, H.K.; Shackelton, L.M.; Millis, A.J. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp. Cell. Res. 1999, 250, 168-173.
10. Hakala, B.E.; White, C.; Recklies, A.D. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J. Biol. Chem. 1993, 268, 25803-25810.
11. Lee, J.H.; Kim, S.S.; Kim, I.J.; Song, S.H.; Kim, Y.K.; In Kim, J.; Jeon, Y.K.; Kim, B.H.; Kwak, I.S. Clinical implication of plasma and urine YKL-40, as a proinflammatory biomarker, on early stage of nephropathy in type 2 diabetic patients. J. Diabetes Complicat. 2012, 26, 308-312.
12. Bojesen, S.E.; Johansen, J.S.; Nordestgaard, B.G. Plasma YKL-40 levels in healthy subjects from the general population. Clin. Chim. Acta 2011, 412, 709-712.
13. Kim, H.R.; Jun, C.D.; Lee, K.S.; Cho, J.H.; Jeong, E.T.; Yang, S.H.; Lee, Y.J.; Park, D.S. Levels of YKL-40 in pleural effusions and blood from patients with pulmonary or pleural disease. Cytokine 2012, 58, 336-343.
14. Létuvé, S.; Kozhich, A.; Arouche, N.; Grandsaigne, M.; Reed, J.; Dombret, M.C.; Kiener, P.A.; Aubier, M.; Coyle, A.J.; Pretolani, M. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J. Immunol. 2008, 181, 5167-5173.
15. Østergaard, C.; Johansen, J.S.; Benfield, T.; Price, P.A.; Lundgren, J.D. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin. Diagn. Lab. Immunol. 2002, 9, 598-604.
16. Kronborg, G.; Ostergaard, C.; Weis, N.; Nielsen, H.; Obel, N.; Pedersen, S.S.; Price, P.A.; Johansen, J.S. Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease. Scand. J. Infect. Dis. 2002, 34, 323-326.
17. Rathcke, C.N.; Persson, F.; Tarnow, L.; Rossing, P.; Vestergaard, H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 2009, 32, 323-328.
18. Ober, C.; Tan, Z.; Sun, Y.; Possick, J.D.; Pan, L.; Nicolae, R.; Radford, S.; Parry, R.R.; Heinzmann, A.; Klaus, A. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N. Engl. J. Med. 2008, 358, 1682-1691.
19. Xie, F.; Qian, Q.; Chen, Z.; Ma, G.; Feng, Y. Chitinase 3-like 1 gene-329G/A polymorphism, plasma concentration and risk of coronary heart disease in a Chinese population. Gene 2012, 499, 135-138.
20. Park, H.Y.; Jun, C.D.; Jeon, S.J.; Choi, S.S.; Kim, H.R.; Choi, D.B.; Kwak, S.; Lee, H.S.; Cheong, J.S.; So, H.S., et al. Serum YKL-40 levels correlate with infarct volume, stroke severity, and functional outcome in acute ischemic stroke patients. PLoS One 2012, 7, e51722.
21. Johansen, J.S.; Schultz, N.A.; Jensen, B.V. Plasma YKL-40: A potential new cancer biomarker? Future Oncol. 2009, 5, 1065-1082.
22. Rathcke, C.N.; Vestergaard, H. YKL-40-An emerging biomarker in cardiovascular disease and diabetes. Cardiovasc. Diabetol. 2009, doi:10.1186/1475-2840-8-61.